Every patient’s experience is different, and only your prescribing physician can tell you what to expect in your specific case. But the published clinical data on semaglutide and tirzepatide gives a general, honest picture of the first weeks of treatment — including the parts that aren’t comfortable.
Dosing starts low, on purpose
Both drug classes are started at a low dose and increased gradually — for tirzepatide, for example, prescribing information describes starting at 2.5 mg with increases in 2.5 mg increments no sooner than every four weeks, up to a maximum of 15 mg. This slow titration exists specifically to reduce gastrointestinal side effects, not to delay results. Your physician sets your actual schedule based on how you respond.
The most common early side effects
Across the FDA prescribing information for these medications, the most frequently reported adverse reactions are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These tend to be most noticeable around dose increases and often ease as your body adjusts. Injection-site reactions are also commonly reported for the injectable forms.
None of this is a guarantee of what you personally will experience — some people notice very little, others need a slower titration schedule, and that’s a normal conversation to have with your provider rather than something to push through silently.
What should prompt a call to your provider
The prescribing information for these medications includes warnings that are worth knowing in plain language, not just in fine print: signs of pancreatitis (persistent, severe abdominal pain), gallbladder problems (pain in the upper right abdomen, fever, yellowing skin or eyes), signs of a serious allergic reaction (swelling of the face/lips/tongue, difficulty breathing), and any mood or thinking changes. If you notice any of these, contact your care team — don’t wait for your next scheduled check-in.
Follow-up matters more than the first dose
Our hybrid model exists because the first injection isn’t the finish line — it’s the start of a monitoring relationship. Expect scheduled check-ins where your physician reviews how you’re tolerating the medication, adjusts your dose if needed, and confirms it’s still the right fit. Results and pacing vary by person; nothing about your first month predicts anyone else’s outcome, and no outcome is guaranteed.
Sources: FDA prescribing information — Wegovy (semaglutide) · FDA prescribing information — Zepbound (tirzepatide)
This article is for informational purposes only and is not medical advice. Read our Medical Disclaimer.